The role of an automated frailty score (electronic frailty index) in improving outcomes for cancer patients in chemotherapy
- Conditions
- CancerMalignant neoplasm
- Registration Number
- ISRCTN28080501
- Lead Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 25
1. Stakeholders (n=10)
1.1. 5 Medical and Clinical Oncologists, General Practitioners, Geriatricians
1.2. 5 Chemotherapy and Specialist Nurses
2. Patients (n=10)
2.1. 2 patients aged 60 - 70 with newly diagnosed stage II or III breast cancer and 2 >70 years old
2.2. 3 patients with stage 3 colon cancer (1 60 - 70 years old and 2 >70 years old)
2.3. 3 patients with Stage IIIB-IV non-small cell lung cancer (1 - 60-70 years old and 2 >70 years old)
3. Carers (n=5) Purposely selected for gender (men =3, women =2) and relationship to the patient (partner =3 or child =2)
1. Stakeholders, patients or carers who do not fulfil the criteria described above
2. Are unable to participate in an interview
3. Do not speak/understand English
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Work-package 1:<br>30 day chemotherapy mortality and hospital admissions during chemotherapy.<br>Information will be taken from historical systemic chemotherapy dataset (SACT) records 2013 - 2016 of patients with breast, lung and colorectal cancer. The data will be obtained from the following databases: The Clinical Practice Research Datalink (CPRD), ResearchOne database and Royal College of GPs (RCGP) Research and Surveillance Centre.
- Secondary Outcome Measures
Name Time Method Work-package 2: <br>1. The acceptability of eFI (electronic frailty index) will be measured using interview data collected at a single time point that will be analysed with Framework Analysis<br>2. The suitability of the endpoints for a future definitive study - this will be decided once the data from WP1 shows the link between eFI and risk of dying from chemotherapy and risk of admission during chemotherapy. If eFI has a predictive power (the poorer the eFI score the higher the chance of complications) this will be deemed as a suitable endpoint for a future trial<br>3. The overall accuracy between hospital derived eFI and GP-medical records derived eFIGP-eFI) - the eFI and GP-eFI will be directly compared to assess the difference in score<br>4. The ease of access to GP-eFI and HES eFI - this will be a descriptive analysis of the time it takes to extract data and obtain relevant agreements